2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 02:34, 18 December 2023
, 18 December 2023→Clinical Trials
| Line 438: | Line 438: | ||
* Hypertension patients display significantly lower blood cell NAD+ levels, and taking NMN increases their blood cell NAD+ levels by ~43%. | * Hypertension patients display significantly lower blood cell NAD+ levels, and taking NMN increases their blood cell NAD+ levels by ~43%. | ||
* Adults with hypertension have cells lining blood vessels — endothelial cells — with elevated concentrations of the NAD+ consuming enzyme CD38, which partially explains their lower NAD+ levels. | * Adults with hypertension have cells lining blood vessels — endothelial cells — with elevated concentrations of the NAD+ consuming enzyme CD38, which partially explains their lower NAD+ levels. | ||
|- | |||
|{{pmid text|37862582}} | |||
| | |||
| | |||
| | |||
|} | |} | ||